Aripiprazole Solution
Product Images NDC 70752-114

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70752-114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quagen Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cartonlabel (Cartonlabel)

Aripiprazole Oral Solution 1 mg/mL packaging label from Quagen Pharmaceuticals LLC. The carton includes storage instructions, tamper-evident seal warnings, pharmacist dispensing instructions, and batch information. The package size is 150 mL in one bottle, and the product is labeled Rx Only with the NDC 70752-114-07. It is indicated as an oral solution dosage form.*

FDA Label Image

Chemstruc (Chemstruc)

Chemical structure of aripiprazole, showing its molecular connectivity including dichlorophenyl, piperazine, and quinolinone moieties.*

FDA Label Image

Containerlabel (Containerlabel)

Label for Aripiprazole Oral Solution 1 mg/mL by Quagen Pharmaceuticals LLC, presented as a 150 mL prescription oral solution. The label includes storage instructions, tamper-evident seal warning, and indicates dispensing of the enclosed medication guide to patients. Manufacturer location and a barcode are also visible.*

FDA Label Image

Figure1 (Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for aripiprazole pharmacokinetics. The x-axis represents change relative to reference (without interacting drug) from 0 to 3. Various drugs affecting CYP3A4, CYP2D6, gastric acid blockers, and others are listed on the y-axis, with their impact on AUC and Cmax of aripiprazole shown as data points with error bars.*

FDA Label Image

Figure2 (Figure2)

A pharmacokinetic chart titled "Effect of Other Drugs on Aripiprazole" showing the fold change and 90% confidence interval for dehydro-aripiprazole concentrations. It compares changes in AUC and Cmax relative to a reference without interacting drugs for various inhibitors, inducers, gastric acid blockers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to reference (without interacting drug) from 0 to 3, illustrating pharmacokinetic parameters such as AUC and Cmax for each drug.*

FDA Label Image

Figure4 (Figure4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic changes (AUC and Cmax) in special populations relative to reference groups. It compares CYP2D6 poor vs. extensive metabolizers, gender differences (female vs. male), age groups (18-64 vs. >65 years), hepatic impairment levels (mild, moderate, severe vs. normal), and severe renal impairment, with data points and confidence intervals plotted along the x-axis of change relative to reference values.*

FDA Label Image

Figure5 (Figure5)

A chart showing the fold change and 90% confidence intervals of Dehydro-Aripiprazole pharmacokinetics (PK) for various factors relative to reference. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and renal impairment severity, with AUC and Cmax measurements plotted against the change relative to reference on the x-axis.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier curve comparing the proportion of subjects with relapse over days from randomization between two groups: Aripiprazole and Placebo. The x-axis shows days from randomization (0 to 182), and the y-axis displays the proportion with relapse (0 to 1). The graph includes a table below indicating the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure7 (Figure7)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole oral solution 1 mg/mL to placebo. The graph plots relapse proportion on the vertical axis and days from randomization on the horizontal axis, with subject numbers at risk listed below the timeline. Aripiprazole is represented by a solid line and placebo by a dashed line.*

FDA Label Image

Figure8 (Figure8)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over time from randomization (days) for Aripiprazole solution 1 mg/mL versus placebo. The chart includes a solid line for Aripiprazole and a dashed line for placebo, with the number of subjects at risk listed below the x-axis at various time points up to 364 days.*

FDA Label Image

Figure9 (Figure9)

A line chart showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The chart compares three groups: ARIP-LOW, ARIP-HIGH, and PLACEBO, with the least-squares mean change in score on the vertical axis and weeks of treatment on the horizontal axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.